March 2016, Vol 9, Seventh Annual Payers' Guide

Drug Updates, FDA Approvals, Payers' Guide

Welcome to the Seventh Annual Payers' Guide to New FDA Approvals

Drug Updates, FDA Approvals, Payers' Guide

Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis

Drug Updates, FDA Approvals, Payers' Guide

Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure

Drug Updates, FDA Approvals, Payers' Guide

Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals

Caroline Helwick

Drug Updates, FDA Approvals, Payers' Guide

Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure

Drug Updates, FDA Approvals, Payers' Guide

Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia

Lisa A. Raedler, PhD, RPh

1
2
3
4
5

Page 3 of 5
Results 21 - 30 of 43

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.